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 Pancreatic cancer is a lethal disease with very poor prognosis as it is one of the 
leading causes of cancer related deaths worldwide. Pancreatic cancer may manifest in 
different ways and there are a number of different genetic mutations that can lead to 
carcinomas of the pancreas. This study reviewed some of the genetic alterations seen in 
pancreatic cancer and how they appear in the context of disease progression. While 
progress has been made in identifying genetic mutations that may contribute to pancreatic 
cancer, more work has to be done to solidify biomarkers and potentially contribute to 
early detection of the disease.       
 Pancreatic cancer is often asymptomatic until late stages of disease, which is why 
it is often diagnosed at such a progressed state. Late detection contributes to its poor 
prognosis as it unlikely to have curative potential at such a late stage. Approach to 
treatment generally depends on the stage at diagnosis. This study reviewed a number of 
different treatment options including surgical resection, chemotherapy, and targeted 
therapy. Surgical resection is currently considered the only cure for pancreatic cancer. 
The other treatment options may be helpful in reducing recurrence of cancer and/or 
increasing survival. Targeted therapy is a very recent approach that is currently used as a 
treatment to manage pancreatic cancer with fairly positive outcomes. Hopefully, with 
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further exploration into this individualized approach and modification of current targeted 
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The pancreas is essential to human survival, as it is an organ that demonstrates 
both endocrine and exocrine function. Function depends on the different cell types that 
are found in the pancreas. The endocrine component is arranged into discrete Islets of 
Langerhans, which are surrounded by the exocrine cells1.  
The endocrine function of the pancreas works to regulate and maintain blood 
sugar levels. There are 5 different endocrine cells that are found in the islet of 
Langerhans. These cells are responsible for secreting the hormones that control blood 
sugar2. The two most important hormones in regulating blood sugar include insulin and 
glucagon. Insulin is secreted by the beta cells of the pancreas and decreases blood sugar 
levels by facilitating the uptake of glucose into the cell to be utilized for energy3. 
Glucagon is secreted by the alpha cells of the pancreas and works to increase blood sugar 
levels by increasing the processes of glucose metabolism. The other hormones of the 
pancreas include somatostatin, ghrelin, and pancreatic polypeptide. Somatostatin is an 
inhibitory hormone which prevents the release of insulin and glucagon4. Ghrelin is 
involved in orexigenic effect, control of energy expenditure, and peripheral 
gastroenteropancreatic actions5. Pancreatic Polypeptide works to suppress exocrine 
pancreatic secretions and can be considered a satiety hormone.  
One of the major pathologies of the endocrine pancreas is Diabetes Mellitus. This 
is a chronic disease that occurs when the pancreas cannot produce insulin or cannot 
utilize insulin effectively. This leads to unregulated and high blood sugar levels which 
causes damage to the tissues of the body overtime. There are two common types of 
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diabetes mellitus. Type 1 diabetes is considered to be autoimmune, where the beta-cells 
of the pancreas are destroyed and therefore insulin cannot be produced sufficiently. Type 
1 diabetes is present in about 5–10% of Diabetes Mellitus cases and generally has an 
earlier onset, being diagnosed in children, teens, and young adults6. Type 2 diabetes is 
commonly characterized by insulin resistance along with hyperglycemia and insulin 
deficiency. Consistently high levels of sugar in the blood lead to serious health problems 
that effect many other organs including the heart and kidneys. Type 2 diabetes accounts 
for a majority of diabetes mellitus cases and results from an interaction of genetic, 
environmental, and behavioral risk factors7.  
The exocrine function of the pancreas produces enzymes that are critical for 
digestion and also secretes bicarbonate-rich fluid that neutralizes gastric secretions in 
order to optimize pH levels for duodenal digestion8. The exocrine pancreas contains two 
major cell types: acinar cells and duct cells. The acinar cells are responsible for 
synthesizing, storing, and transporting digestive enzymes. These crucial enzymes include 
proteases, amylase, lipase, and nucleases. The duct cells are responsible for secreting 
bicarbonate and mucins which neutralize gastric secretions. They also form a network of 
tubules which are involved in delivering enzymes produced by the acinar cells to the 
duodenum. Interestingly, many tumor cells of pancreatic cancer share properties similar 
to the pancreatic ductal cells.  
Pathologies of the exocrine pancreas can lead to insufficient breakdown and 
absorption of nutrients which can cause malnutrition. A major pathology of the exocrine 
pancreas is pancreatic ductal adenocarcinoma; the most common and fatal form of 
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pancreatic cancer. Additional pathologies of the pancreas include: acute pancreatitis, 
chronic pancreatitis, and cystic fibrosis; which all lead to an increased risk of pancreatic 
cancer. Cystic fibrosis can affect the pancreas by thickening pancreatic secretions and 
clogging the ducts of the pancreas, which can lead to significant pancreatic disease9. 
Acute pancreatitis is inflammation of the pancreas that lasts less than 3 weeks and is 
often caused by gallstones or alcohol abuse. Acute pancreatitis can lead to chronic 
pancreatitis10. Chronic pancreatitis is a progressive fibroinflammatory disease that can 
occur in the ducts of the pancreas. It can be caused by an interaction of environmental 
and genetic factors. It can also be hereditary or autoimmune. Pancreatitis can lead to 
scarring and permanent damage of the pancreas. This damage impairs pancreatic function 
and can also lead to diabetes and pancreatic cancer. Chronic pancreatitis increases the 




Figure 1: Cells of The Pancreas12 
 
This figure shows the different cells of the pancreas and an example of how they may be 
arranged. The endocrine cells produce insulin, glucagon, somatostatin, pancreatic 
polypeptide, and ghrelin (not shown). The exocrine cells are acinar and duct cells and 









Pancreatic cancer is a lethal disease with a poor prognosis as it is currently the 
fourth leading cause of death from cancer worldwide. It has a higher death rate in more 
developed countries and is the third most common cause of death from cancer in the 
United States13. It has a higher incidence in males than in females. Interestingly, 
pancreatic and kidney cancers are the only two cancers where white patients have lower 
survival rates than black patients14. The incidence of pancreatic cancer is increasing, 
which could be due to the fact that people are living longer, as pancreatic cancer rarely 
occurs before the age of 40 and mostly frequently occurs between the 6th and 8th decades 
of life15. Over 90% of individuals who develop pancreatic cancer die from the disease 
and the 5-year survival rate is one of the lowest of all cancers at just 9%14. 
         The cause of pancreatic cancer is multifactorial, with family history and cigarette 
smoking being dominant. Individuals with a first-degree relative with pancreatic cancer 
are at a 2.3 fold increased risk of developing pancreatic cancer16. Other risk factors for 
pancreatic cancer include diabetes mellitus, obesity, alcohol abuse, dietary factors, 
chronic pancreatitis, and H. pylori infection17. There is currently no efficient screening 
procedure for pancreatic cancer and symptoms don’t typically show up until the cancer is 
past the curative stage. Pancreatic cancer presents in the clinic most commonly as severe 
abdominal pain. Other common symptoms include jaundice, back pain, weight loss, 
diabetes mellitus, glucose intolerance, and acute pancreatitis.  
 There are two main types of pancreatic cancer: pancreatic adenocarcinoma and 
pancreatic neuroendocrine tumor (PaNET). PaNET occurs in the endocrine tissue of the 
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pancreas and is much less common, accounting for only about five percent of cases of 
pancreatic cancer18. Pancreatic adenocarcinoma, which arises from the exocrine function 
of the pancreas, is the most common type of pancreatic cancer. It accounts for about 85% 
of cases and has extremely poor prognosis with the 1-year survival rate after diagnosis 
being about 24%. Pancreatic adenocarcinoma has such poor prognosis in comparison to 
PaNET because it typically does not present until stage III or IV, at which point some 
cases are not even candidates for surgical treatment19. Diagnosis is often missed and 
pancreatic cancer is the most common tumor found during autopsies20. 
The therapies explored in this paper will focus on targeting pancreatic 
adenocarcinoma, as it is the most common and lethal form of pancreatic cancer. 
Advances in treatment for pancreatic cancer are challenging because of such late stage 
diagnosis. Temporal trends illustrate increases in both the incidence and mortality of 




Figure 2: Predicted Trends13 
This figure represents a prediction of pancreatic cancer incidence and mortality for the 
years 2018 to 2040 for different continents. It is expected that incidence and mortality for 
pancreatic cancer will increase in almost every population.  
 








Pancreatic cancer demonstrates both inherited (germ line) mutations and somatic 
gene mutations. Genetic mutations found in pancreatic cancer are commonly found in 
other types of cancers, including breast, lung, and colon cancers. Determining which 
genetic mutation(s) are present in a case of pancreatic cancer can help guide treatment 
options, specifically targeted therapies.  
About 3% to 7% of individuals who present with pancreatic ductal 
adenocarcinoma, harbor a mutation in BRCA1 or BRCA221. These are pathogenic 
germline alterations that can increase an individual’s risk of developing pancreatic 
cancer. Specifically, BRCA2 is found in about 7.3% of familial pancreatic cancer patients 
and can increase risk of pancreatic cancer up to 20-fold. BRCA2 is a tumor suppressor 
gene that is also involved in repairing double strand breaks of DNA during the cell cycle. 
BRCA2 has additional roles in cytokinesis, centrosome duplication, and cell death22. 
BRCA2 has been found in breast, ovarian and prostate cancers. BRCA2 mutations are 
particularly sensitive to therapies that include radiation and Mitomycin C, as these 
produce double strand breaks and DNA cross-linking23. The use of poly-ADP ribose 
polymerase (PARP) inhibitors is currently being explored as an option of treatment in 
patients with pancreatic cancer who harbor mutations in the BRCA1 and BRCA2 genes. 
Potentially the most common mutation present in patients with pancreatic ductal 
adenocarcinoma (PDAC) is the KRAS2 oncogene. This is an activating mutation that is 
found in approximately 90-95% of pancreatic cancer cases23. KRAS is a GTPase that is 
part of the RAS/MAPK signaling pathway. When it is bound to GTP it is able to bind and 
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activate RAF family kinases. This can lead to regulation of transcription factors and 
signal for cell growth and proliferation. When KRAS is mutated, it can cause constitutive 
activation and lead to uncontrolled cell proliferation which leads to the development of 
cancer24.  
A high frequency of KRAS2 mutations are also found in pancreatic intraepithelial 
neoplasias (PanINs), which are precursor lesions of pancreatic cancer23. This supports the 
mutation of KRAS2’s role as an initiating event in pancreatic cancer. In addition, 
constitutive RAS signaling allows the maintenance of pancreatic cancer. Current 
therapies aimed at targeting this pathway include EGFR inhibitors. The epidermal growth 
factor receptor (EGFR), is a transmembrane receptor that is involved in initiating the 




Figure 3: MAPK Signaling Pathway25 
This figure demonstrates the MAPK signaling pathway. The MAPK signaling pathway 
mediates extracellular signals to produce a cascade that reaches the nucleus and elicits a 
response. The signal is communicated from the receptor on the cell surface. This pathway 




 KRAS2 is generally found in combination with an accumulation of other 
mutations. These include inactivating mutations in tumor suppressor genes 
p16/CDK2NA, TP53, and SMAD4/DPC. The gene p16/CDKN2A is a cyclin dependent 
kinase inhibitor that keeps cell division in check by slowing the progression of the cell 
cycle from the G1 phase to the S phase26. The loss of function of the p16/CDKN2A is 
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present in about 90% of pancreatic cancer cases23. TP53 is a protein with various roles 
including controlling the checkpoints of the cell cycle, activating DNA repair, and 
regulating apoptosis. When TP53 loses its function, cells are able to survive and 
proliferate regardless of damage to its DNA. This leads to an accumulation of damage 
and an increase of mutations. Inactivation of TP53 is common to many cancers and is 
seen in approximately 50-75% of cases of pancreatic cancer27. SMAD4/DPC is a protein 
that mediates the transforming growth factor- beta (TGF-B) pathway. It plays significant 
roles in inhibiting cell growth and regulating apoptosis28. SMAD4 is inactivated in about 
55% of cases of pancreatic cancer23.  
Additional mutations that can be common to cases of pancreatic cancer are 
mutations in the hMLH1 and hMSH2 genes23. These mutations cause microsatellite 
instability and lead to defects in DNA mismatch repair29. Individuals with these germline 
mutations can be at an increased risk for pancreatic cancer as well as an elevated risk for 
earlier onset of pancreatic cancer30. Tumors involving these mutations appear to have 




DISEASE PROGRESSION:  
While early detection of PDAC has been quite challenging, there are precursor 
lesions that can be identified. Some of the common precursor lesions include pancreatic 
intraepithelial neoplasias (PanINs), intraductal papillary mucinous neoplasms (IPMNs), 
and mucinous cystic neoplasms (MCNs)31. PanINs are microscopic and the most 
prevalent precursor lesions found in PDAC. While IPMNs and MCNS are macroscopic 
and can be detected using radiation31.   
MCNs are lined by mucin-producing epithelial cells. They generally occur in the 
body or tail of the pancreas and are not connected to the pancreatic ductal system. MCNs 
are particularly found in women and up to 16% are found in association with invasive 
carcinomas31. MCNs are much less likely than the other precursor lesions to progress to 
cancer.  
  IPMNs are papillary structures that project into the main pancreatic duct. These 
are generally mucinous tumors found in the head of the pancreas. These lesions are found 
in up to 40% of cases and occur equally in both men and women. As IPMNs progress 
they accumulate more genetic abnormalities and exhibit a higher degree of dysplasia32. 
The most common precursor lesions, PanINs, can be found anywhere in the 
pancreas and have a combination of flat and papillary structures as part of their histology. 
There are 3 stages of PanINs that progress to metastatic carcinomas. PanIN-1 is classified 
as a low grade lesion and contains mutations in the KRAS2 gene23. This further supports 
the role of the KRAS2 gene mutations as an initiating event in the formation of 
pancreatic cancer. PanIN-1 lesions may also contain telomere shortening which enable 
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more chromosomal abnormalities to accumulate. These lesions can progress to 
intermediate PanIN-2 lesions which contain inactivating mutations of the p16/CDKN2A 
genes. This can further progress to more advanced Pan-IN-3 lesions with inactivating 
mutations in TP53, SMAD4, and BRCA2 genes23. The accumulation of these mutations 
along with the histological progression of the lesions can lead to the initiation and 
maintenance of PDAC. While these lesions are microscopic, being able to identify them 
could have significance in detecting pancreatic cancer in its early stages and be 
fundamental in developing a method for screening. It has also been estimated that it could 
take up to 12 years for PanIn-3 lesions to transform into pancreatic cancer33. This further 
illustrates the impact a screening protocol can achieve as this is a moderate window for 
early detection.   
 
Figure 4: Histology of PanIN lesions34 
This figure shows the pathogenesis of pancreatic lesions by histological characteristics. 
(A) represents a normal duct. (B) represents a low grade pancreatic intraepithelial 
neoplasia (PanIN).  (C) represents a high grade PanIN.  
 
 




Figure 5: Disease Progression Model of Pancreatic Cancer24 
 
This figure illustrates the accumulation of genetic mutations and how they are associated 
with the progression of precursor lesions. As the number of mutations increase, the 









Pancreatic cancer is often not diagnosed until it is in its late stages. This has 
contributed to the challenge of successful treatment. Early detection has proved difficult 
because the pancreas is not palpable and there is a lack of identifiable biomarkers. 
Additionally, pancreatic cancer is often asymptomatic until a very advanced stage. 
Symptoms can also vary based on the location of the tumor. A tumor in the head of the 
pancreas can cause a blockage of the common bile duct and lead to symptoms including: 
weight loss, jaundice, nausea, vomiting, dark urine, and light colored stools34. A tumor in 
the body or tail of the pancreas produces severe abdominal pain that radiates to the back 
or down the sides of the body.  
A biomarker that has been routinely used for the management of pancreatic 
cancer is serum cancer antigen 19-9 (CA 19-9)35. This is an antigen that is released by 
cancer cells of the pancreas and it thus considered a tumor marker. High levels of CA 19-
9 have been found in individuals who have already been diagnosed with pancreatic 
cancer. However, it appears to have a low positive predictive value in asymptomatic 
individuals and therefore its ability to screen in an asymptomatic population cannot be 
determined effective. Due to this, CA 19-9 is more commonly used to monitor cancer 
progression and tumor response to therapy36. While CA 19-9 is the only tumor marker 
that is FDA approved for the management of pancreatic cancer, others are currently being 
explored including: carcinoembryonic antigen (CEA), osteopontin (OPN), and 
macrophage inhibitory cytokine 1 (MIC-1)35. With more research, these markers have the 
potential to be used for the early detection of pancreatic cancer in the future.  
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Reliable imaging techniques are important in order to detect and stage pancreatic 
cancer accurately. Some imaging techniques that are currently used are abdominal 
ultrasound, computerized tomography (CT), magnetic resonance imaging (MRI), positron 
emission tomography (PET), and endoscopic ultrasound (EUS)37. CT is the most used 
imaging technique as it is the most available relative to EUS and MRI. CT demonstrates 
good sensitivity and specificity for tumors greater than 2cm in size38. This limits its 
effectiveness for early detection of PDAC. MRI may exhibit more accuracy in evaluating 
smaller tumors but it’s use is limited by its higher cost. Furthermore, EUS has 
demonstrated the most effective technique for diagnosing and staging pancreatic cancer 
as it is able to identify lesions as small as 2-5mm. It exhibits an accuracy of over 90%. 
EUS has a significant role in staging the tumor prior to operation and determining the 
possible resectability37. EUS is also unique from other imaging techniques as it provides 





Identifying the stage of pancreatic cancer can guide an individual in choosing a 
treatment approach. The stage of pancreatic cancer is generally determined using the 
tumor-node-metastasis (TNM) classification system. The size, dimensions, and extension 
of the primary tumor are classified by (T) and range from TX to T439. TX represents a 
stage where no primary tumor can be assessed. T4 represents an unresectable tumor that 
is greater than 2cm in size and involves major blood vessels40. The nodal classification 
ranges from NX to N1 and assesses whether or not the cancer has spread to regional 
lymph nodes. The metastatic classification ranges from M0 to M1 and indicates whether 
or not the tumor has spread to other organs. Pancreatic cancer most commonly 
metastasized to the liver but also commonly spreads to the lungs, bones, and brain41. 
Stage I is confined to the pancreas with no spread to lymph nodes or other organs 
and is generally a small primary tumor. Stage II involves the growth of the primary tumor 
into nearby tissues but does not demonstrate any metastasis. Stage I and Stage II are 
usually resectable and have a better prognosis34. Stage III tumors are greater than 2cm in 
size and have spread to nearby lymph nodes with the propensity to spread to distant 
organs. Stage IV tumors involve some growth into other organs and possible metastasis 
into other organs as well. Stage III and Stage IV can present as borderline resectable or 









Table 1: TNM Classification for Pancreatic Cancer40  
 
This table illustrates how pancreatic cancer is classified in terms of the primary tumor, 
lymph nodes, and metastasis. These classifications are further used to determine the stage 





Table 2: Staging of Cancer34 
 
This table represents how TNM categorization would be used to evaluate the stage of 
cancer. Identifying the stage can help to guide treatment approach.   
  
UICC DISEASE STAGE T staging N staging M staging 
 
STAGE 0 Tis N0 M0 
STAGE IA T1 N0 M0 
STAGE IB T2 N0 M0 
STAGE IIA T3 N0 M0 
STAGE IIB T1–3 N1 M0 
STAGE III T4 Any N M0 







Despite various treatment options for the management of pancreatic cancer, 
prognosis and survival of the disease still remains quite poor. Current treatment options 
for pancreatic cancer include: surgical resection, radiation therapy, chemotherapy, 
targeted therapy, and immunotherapy. Approaches to treatment are dependent on where 
the tumor is located and what stage the cancer presents as in the patient. While surgical 
resection is currently considered the only cure for pancreatic cancer, it can be used in 
combination with previous or subsequent use of chemotherapy42. Targeted therapies, such 
as the use of EGFR inhibitors and PARP inhibitors, are currently being explored and 
becoming more common in the management of pancreatic cancer. While these have not 
exhibited the ability to cure pancreatic cancer, they have demonstrated an increase in 
survival span. With further study and fine-tuning, these therapies may have the capacity 
to cure pancreatic cancer and become the standard of care in the future.  
  
SURGICAL RESECTION  
While surgical resection is considered the only possible cure for pancreatic 
cancer, it still has poor prognosis and survival. Only about 20% of PDAC cases are able 
to be operated on34. This is generally because at the time of diagnosis the cancer has 
already spread to distant sites and thus it is not advised to operate. Surgical resectability 




Figure 6: Anatomy and Surgical Resectability of Pancreatic Cancer15 
This figure shows the anatomy of the pancreas as well as the structures associated with it. 
Pancreatic cancers are categorized on a continuum from resectable to unresectable 
depending on the involvement of adjacent structures and metastases. 
 
 
About 98% of tumors that arise in the area of the pancreas are malignant and have 
the potential to metastasize. Of these tumors, about 65% are found in the area around the 
head or neck of the pancreas43. These cancers may be subject to surgical resection by a 
pancreaticoduodenectomy, also known as the Whipple procedure. However, the tumor is 
less likely to be resected if it has involvement with major arteries, including the celiac 
trunk, superior mesenteric artery, and the hepatic artery15. The Whipple procedure is a 
complex surgery that removes the head of the pancreas, the curve of the duodenum, the 
gallbladder, and the common bile duct. The biliary system and digestive tract are then 
reconnected so that the digestive process is still able to occur (Figure 7).  
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Figure 7: The Whipple Procedure 
The illustration represents the pancreas before and after the Whipple procedure. This 
procedure is used when a tumor is able to undergo surgery for resection and is located 
near the head of the pancreas.  
 
 
Around 15–20% of the tumors are found at the tail of the pancreas and are subject 
to surgical procedure by distal pancreatectomy3. These procedures are also limited if the 
tumor involves major arteries. A distal pancreatectomy removes the body and tail of the 
pancreas along with the spleen44. This resection tends to be more uncommon than the 
Whipple procedure because tumors located in the body or tail of the pancreas usually 
present at a later stage with a bigger tumor with respect to carcinomas found in the head 
of the pancreas. Due to this late stage diagnosis, resection is generally not recommended 
as a treatment option.   
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And in some cases, if the cancer has spread or occurring in multiple parts of the 
pancreas, a total pancreatectomy can be done. This usually consists of removal of the 
entire pancreas, the common bile duct, a portion of the abdomen, a portion of the small 
intestine, the gallbladder, and the spleen. This is the rarest pancreatic resection surgery. It 
is followed by endocrine and exocrine insufficiency and it has the highest mortality rate 
of all pancreatic surgeries45.  
Surgical resection of the pancreas has made many advancements over time and 
the morbidity and mortality from the surgical procedure itself has decreased drastically as 
it is now quite low46. However, survival after surgical resection is still not very promising 
with very low 5-year survival rates. In one study done, median survival following 
pancreatic resection was about 27 months. Survival time after resection is associated with 
the stage of pancreatic cancer. Factors that lead to favorable prognosis include: absence 
of lymph node metastasis, absence of portal vein invasion, absence of extra neural 
pancreatic invasion, and tumor sizes less than 20mm47. 
Despite the idea that surgical resection is the only cure for PDAC, it is 
realistically not a cure for many patients. Even with the curative surgery, most patients 
experience a recurrence of cancer and metastasis which leads to fatality. And thus surgery 
may not be a cure but an option to increase survival time.    
 
SURGICAL RESECTION WITH COMBINATION THERAPY:  
The goal of a resection is to completely excise the primary tumor as well as any 
nearby lymph nodes that could contain remnants of metastasis. Pancreatic cancers that 
are resectable or borderline resectable can be used in combination with therapies in an 
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effort to decrease the chances of recurrence and metastasis and thus increase the length of 
survival. This could include therapeutic treatment before and/or after surgery. Overall, 
using multiple forms of therapy has demonstrated an improved rate of survival in patients 
who present with operable PDAC48.   
Therapies used prior to surgery, neoadjuvant therapies, are used in an effort to 
shrink a tumor. This would help to increase the chances of completely excising a tumor 
with clear margins during resection. The methods used include chemotherapy and 
radiation therapy49. Treatment is generally a short time period of about 2-3 months of 
chemotherapy before surgical resection. This time period enables the opportunity to 
explore the cytology of the tumor. This can help assess if targeted therapy would be 
beneficial as a treatment approach. Neoadjuvant therapy may also eliminate micro 
metastases which were not detected by imaging49. Targeting these micro metastases early 
on can decrease their propensity to spread further and cause fatality.  
If a tumor is borderline resectable, neoadjuvant therapy may also be considered as 
a treatment option as shrinking the tumor and sharpening the margins may transition a 
tumor to a more resectable categorization. However, there is approximately a 20% chance 
that a tumor will progress and become unresectable in the neoadjuvant therapy period49. 
Therefore, it is important to evaluate if a tumor is rapidly progressing or has already 
metastasized. In these cases, neoadjuvant therapies are not viable options.    
While the neoadjuvant therapy approach has exhibited survival success in other 
gastrointestinal cancers, it is still at the experimental phase for pancreatic cancer. 
Neoadjuvant therapy has shown beneficial effects on the T stage, lymph nodes, and 
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resectable margins. In one clinical trial done with neoadjuvant chemoradiation therapy, 
the median survival following resection was 34 months and 5-year survival with 
complete absence of disease occurrence was approximately 33%50. This is a promising 
approach as life expectancy without neoadjuvant therapy is about 26.7 months. 
Neoadjuvant therapy has also been associated with a higher quality of life expectancy51.   
The current standard of care for resectable PDAC is surgical resection followed 
by adjuvant therapy. This approach relies on excising the tumor and then using 
chemotherapy to suppress the growth of any secondary tumors or metastases. Adjuvant 
therapy is typically given for about 6 months and begins about 8–12 weeks after resection 
depending on the health of the patient post-surgery52. Adjuvant therapy has demonstrated 
an improvement in 5-year survival to 20–25% and has shown an increase in the disease-
free survival period52.    
Chemotherapy drugs that have been approved by the US Food and Drug 
Administration and are commonly used for the treatment of PDAC are Gemcitabine, 
Capecitabine, Fluorouracil, Paxlitexil, and Oxaliplatin34. These drugs can be used 
individually or in combination with each other. These are given either intravenously or 
orally. They are generally given in 2 to 3-week cycles for 3–6 months. Chemotherapy is 
generally more effective when drugs are used in combination. However, for those who 
are not healthy enough for combination therapy, single agents are used for management 
of PDAC.  
Gemcitabine (Gemzar) has been considered the standard of care for advanced 
pancreatic cancer since 199753. This is a pyrimidine analog that interferes throughout the 
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process of DNA replication and works to arrest the cell cycle24. It can be used as adjuvant 
therapy after resectional surgery or for cases that are unresectable. In patients who are 
healthy enough to tolerate combination therapy, gemcitabine is used with other agents 
including nab-paclitaxel, oxaliplatin, and capecitabine54. Combining with these agents, 
enhances the sensitivity of germatacibe. In comparison to monotherapy of gemcitabine, 
combination therapy has consistently displayed an increase in median overall survival 
when used in cases of resectable pancreatic cancer42.    
FOLFIRINOX, a consolidation of multiple agents, is another standard 
chemotherapy treatment option. FOLFIRINOX consists of fluorouracil, leucovorin, 
irinotecan, and oxaliplatin55. These work to interfere with the processes of DNA 
replication and transcription24. FOLFIRINOX has shown an overall increase in survival 
and efficacy in studies where it is compared to gemcitabine nab-paclitaxel. However, this 
increase in overall survival has come at the expense of higher toxicity and greater 
experience of side effects. Due to the severe side effects that can impede on quality of 
life, use of FOLFIRINOX should be approached with caution and only recommended in 




Figure 8: FOLFIRINOX vs. Gemcitabine56 
 
This figure shows a Kaplan-Meier curve that estimates overall survival and progression-
free survival in two different treatment groups. There is significance when FOLFIRINOX 
is used in comparison to when gemcitabine is used alone. A shows overall survival; the 
median was 11.1 months in the group receiving FOLFIRINOX (oxaliplatin, irinotecan, 
fluorouracil, and leucovorin). Panel B shows progression-free survival; the median was 
6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group. 
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While chemotherapy is used in the treatment of pancreatic cancer, it is often not 
successful. There are frequently dense desmoplastic reactions associated with the disease 
and pancreatic tumors are surrounded by dense, fibrous tissue growth. This growth can 
make it resistant to chemotherapy34. The first line of treatment for patients who present 
with advanced pancreatic cancer is combination chemotherapy drugs described above, 
FOLFIRINOX and gemcitabine/nab-paclitaxel.  If a patient is not healthy enough to 
tolerate the above combination treatments, gemcitabine alone can be used57. A limiting 
factor in the use of stronger combination chemotherapy agents could be age, as some 
patients who are above the age of 75 could be deemed not fit enough for the side effects 
that can be endured by these agents.  
If the disease progresses to a worse state or severe side effects are experienced by 
the first-line treatment options, second-line treatment options may be attempted. If 
FOLFIRINOX has been tried, a treatment option containing gemcitabine either in 
combination or alone should be attempted.  However, FOLFIRINOX is only 
recommended after gemcitabine combination therapy if a patient is suspected to be  
healthy enough to tolerate it because it is a more aggressive treatment with more severe 
side effects. If FOLFIRINOX and gemcitabine/nab-paxlitaxel have already been tried, the 
next options considered can be fluorouracil (5-FU) and leucovorin in combination with 
other agents. If a case is not suitable to receive multiple agents, then capecitabine may be 
used alone. Currently, 5-FU/liposomal irinotecan has demonstrated the strongest level of 
evidence for second-line treatment57.  
If multiple lines of therapy have been exhausted and a case does not seem to 
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respond successfully, recovery from pancreatic cancer may be unlikely. If this is the case, 
palliative care may be the next step considered. The goal of palliative care is to manage 
symptoms and pain towards the end of life for patients. Cases with a higher intensity of 
pancreatic cancer receive less aggressive treatment in the last days of life. Some palliative 
care options for advanced pancreatic cancer patients include surgical palliation, radiation 




TARGETED THERAPY:  
Targeted therapy is a form of treatment that works by targeting specific genes, 
proteins, and tissues that contribute to the growth and maintenance of cancer cells. The 
drugs utilized in targeted therapy are unique because they aim to identify and attack 
specific cancer cells while minimizing the harm to normal healthy cells. This is different 
from chemotherapy alone which aims to block all rapidly dividing cells instead of 
interfering with molecules associated with carcinogenesis and tumor. Targeted therapy is 
suspected to be more effective and less harmful than chemotherapy. Targeted therapy can 
be used alone or in association with chemotherapy for the treatment of pancreatic 
cancer59.  
Targeted therapy is at the core of precision medicine, which strives to optimize 
efficiency of therapy options for a patient by tailoring treatment based on genetic or 
molecular profiling of each individual. The goal of this is to identify which molecular 
markers are present and then assess which treatment a patient would benefit from most59. 
This enables better efficacy and less toxicity of the drug to the patient. This relies on 
successfully identifying which cells and receptors should be targeted during therapeutic 
treatment.   
There are two categories of targeted therapy: small molecule drugs and 
monoclonal antibodies. Small molecule drugs work by penetrating the cell membrane and 
interfering with signaling pathways and target proteins inside the cells. Monoclonal 
antibodies are not able to penetrate the cell membrane and they work by binding to 
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cancer cell-specific antigens found on the outside of the cell59. The current forms of 
targeted therapy that have been approved by the FDA for the treatment of pancreatic 
cancer are in the small molecule drug category. These two approved therapies are 
Erlotinib and Olaparib, which will be discussed below.      
ERLOTINIB:  
Erlotinib (Tarceva) is a small molecule drug that is a selective EGFR tyrosine 
kinase inhibitor. It works by reversibly binding to the adenosine triphosphate (ATP) 
binding site on the intracellular domain of the EGFR60. By doing so it blocks the 
phosphorylation and initiation of the cascade of transduction signals inside the cell. It can 
specifically interfere with the MAPK and RAS signaling pathways61. These pathways 
have key functions in the regulation of cell processes including proliferation, apoptosis, 
and angiogenesis. When Erlotinib is able to successfully block these processes it limits 
the growth, survival, and metastasis of tumors.  
When EGFR is mutated it causes a constitutive, growth-factor independent 
activation of the downstream pathway that is found in malignant diseases. Deregulation 
of activity can be a result of EGFR gene mutation as well as an increase in the copies of 
this gene and EGFR protein overexpression61. Erlotinib is used in the treatment of 
cancers that demonstrate deregulation in EGFR processes. Mutations in EGFR and 
KRAS are considered predictive biomarkers for the use of Erlotinib60. Pathways that 
overexpress these mutations are commonly found in pancreatic cancers. Erlotinib is 
currently approved as an orally active agent by the FDA for the treatment of non-small 
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cell lung cancer (NSCLC) and pancreatic cancer. Erlotinib has shown impressive 
response rates in NSCLC cases and has shown higher success rates than cytotoxic 
chemotherapy. While Erlotinib has shown a statistical significance in the increase of 
survival of individuals with pancreatic cancer, it requires further modification to 
demonstrate as successful of a response relative to NSCLC cases.  
Erlotinib is approved for the treatment of metastatic NSCLC tumors that exhibit 
deletion or substitution mutations in EGFR. It was FDA approved in 2013 as first-line 
treatment for metastatic NSCLC with these specific mutations after comparing targeted 
therapy, Erlotinib, to the standard chemotherapy treatment62. Similar to pancreatic cancer, 
the majority of patients with NSCLC present at the time of diagnosis in the advanced 
stages of III and IV. The predicted median survival of these patients is approximately 
three to six months. Using the standard chemotherapy treatment, there is about a 30% 
response rate to treatment and only about a 10-month median survival63.  
The “European Tarceva versus Chemotherapy” (EURTAC) was the trial reviewed 
by the FDA that led to the approval of Erlotinib as first-line treatment for NSCLC in the 
United States. This was a randomized trial in patients with NSCLC who harbored EGFR 
mutations and were divided into groups given treatment of either chemotherapy or 
Erlotinib. The chemotherapy used was standard for patients with NSCLC who have 
EGFR mutations, which is platinum-based doublet chemotherapy64. Patients were 
genotyped prior to receiving treatment therapy and only patients with EGFR exon 19 
deletions or exon 21 substitution mutations were included in the trial65. Patients also had 
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to exhibit suitable performance for treatment and the absence of use of any prior 
therapies. Prior to this study, erlotinib was only approved by the FDA as a treatment 
option for patients with locally or advanced metastatic NSCLC who had already tried at 
least one other first-line chemotherapy treatment66. Approval was based on progression-
free survival, response rate, and toxicity.  
The results found in EURTAC showed a significant response rate to the use of 
Erlotinib in relative to chemotherapy. The median progression-free survival was 10.4 
months in patients who received treatment with erlotinib and 5.2 months in patients who 
received treatment with chemotherapy. The median overall survival was not shown to be 
statistically significant though as it was 22.9 months in the erlotinib group and 19.5 
months in the chemotherapy group62. The objective response rate, which demonstrates a 
shrinkage in tumor size, was 65% in the erlotinib group and 16% in the chemotherapy 
group. Additionally, more patients had to modify treatment, by either reduction or delay, 
in the chemotherapy group than the erlotinib group due to adverse response events to 




Figure 9: Chemotherapy vs Erlotinib in NSCLC 
This figure demonstrates a Kaplan-Meier curve for NSCLC that compares the 
progression-free survival in patients who received erlotinib targeted therapy treatment 
versus patients who received standard chemotherapy treatment. Standard chemotherapy 
treatments include cisplatin plus gemcitabine, cisplatin plus docetaxel, carboplatin plus 
gemcitabine, and carboplatin plus docetaxel.  
 
 
Currently, erlotinib is FDA approved for first-line treatment or second-line 
treatment following chemotherapy in NSCLC cases who demonstrate an EGFR mutation. 
Its efficacy and treatment in the use of treatment for NSCLC cases without an EGFR 
mutation has not been established and is not recommended. Erlotinib is also not 
recommended for use in combination with chemotherapy in NSCLC.  
Erlotinib in combination with gemcitabine chemotherapy is currently FDA 
approved for patients who present with locally advanced, unresectable, and metastatic 
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pancreatic cancer. In 2004, the FDA approved erlotinib in combination with concurrently 
administered gemcitabine after a randomized clinical trial that compared treatment of 
gemcitabine plus erlotinib to gemcitabine plus placebo (gemcitabine alone)67. This was a 
phase III clinical trial conducted by the National Cancer Institute of Canada Clinical 
Trials Group (NCIC-CTG) in cooperation with multiple investigators. The study included 
569 patients and took place in 18 countries. The patients chosen for this study had to 
demonstrate locally advanced or metastatic pancreatic cancer. Patients who received prior 
chemotherapy were not included in the study.   
The results of this clinical trial were shown to be statistically significant but still 
low. The patients who received gemcitabine plus erlotinib exhibited a median 
progression-free survival of 3.8 months and a median overall survival of 6.4 months. This 
was compared to the patients who received gemcitabine alone with a median progression-
free survival of 3.5 months and median overall survival of 6.0 months. When 
stratification factors were adjusted for the median survival for gemcitabine plus erlotinib 
vs gemcitabine alone, was 6.24 months versus 5.91 months, respectively. Additionally, 
the 1-year survival of patients who received gemcitabine plus erlotinib was 23.8% versus 
19.4% for patients who received gemcitabine alone. While progression-free survival was 
demonstrated to be statistically significantly longer in this study; the objective response 
rates did not show any significant difference between the two treatment groups68. More 
adverse events occurred in the gemcitabine plus erlotinib group, but they were deemed to 
be mild, low grade events. 
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While the NCIC-CTG study demonstrated significant survival benefits of 
gemcitabine plus erlotinib, it did not show benefit in the context of EGFR mutations. 
However, later studies did show that gemcitabine plus erlotinib was able to better treat 
pancreatic cancer with EGFR mutations than gemcitabine alone60. A clinical study done 
in Taiwan was able to demonstrate a significance of gemcitabine plus erlotinib in 
metastatic pancreatic cancer when EGFR mutations were present69. Patients who received 
gemcitabine plus erlotinib with EGFR mutations had a higher disease control rate than 
patients receiving the same therapy but without EGFR mutations, 85% versus 33%, 
respectively. Patients who received gemcitabine plus erlotinib with EGFR mutations also 
had a significantly longer median progression-free survival of 5.9 months and median 
overall survival of 8.7 months. This can be compared to patients who received 
gemcitabine plus erlotinib without EGFR mutations who had a median progression-free 
survival of 2.4 months and a median overall survival of 6.0 months60. Additionally, this 
study demonstrated consistency with the survival benefit of the combination therapy, 
such that regardless of whether EGFR mutations were present, the group receiving 
gemcitabine plus erlotinib had a higher overall survival than the group who received 
gemcitabine alone.   
It is clear that erlotinib is more effective for overall survival in NSCLC in 
comparison to pancreatic cancer. However, erlotinib does show significant survival 
effects when used to treat pancreatic cancer when compared to other treatment options 
for pancreatic cancer. The mechanism for how EGFR inhibitors works to increase 
survival in pancreatic cancer is poorly understood. One suspected mechanism is that 
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EGFR is overexpressed and this leads to increased EGFR signaling which leads to 
growth and metastasis of cancer and decreases the survival of patients with pancreatic 
cancer67. By targeting this signaling pathway, growth and metastasis may be slowed and 
survival may be extended. Another suspected mechanism is that there is autocrine 
stimulation of the EGFR and this contributes to pathogenesis of pancreatic cancer by 
sustaining cell proliferation67. Inhibiting EGFR tyrosine kinase activity may contribute to 
slowing the replication of cells and therefore prolonging the metastasis.       
 Eventually in patients with both NSCLC and pancreatic cancer overtime 
resistance is acquired to erlotinib and all patients progress to fatal disease states70. While 
it may slow the progression of carcinomas, resistance is eventually acquired to the 
targeted inhibition of kinases. 
This modest increase in survival of patients with pancreatic cancer when 
treatment with erlotinib is utilized is promising though. It establishes a need for further 
research into EGFR mutations and the pathways it involves in association with pancreatic 
cancer. This increase in survival with this targeted treatment shows progress and is a 
small step in the direction towards finding a cure for pancreatic cancer. More research is 
also needed for biomarkers that can establish efficacy of erlotinib.   
 
OLAPARIB 
Olaparib (Lynparza) is a small drug molecule that is a poly ADP ribose 
polymerase (PARP) inhibitor. PARPs are a family of enzymes that have a critical role in 
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a number of cellular processes. These include the processes of structuring chromatin, 
transcription, replication, recombination, and DNA repair71. PARP is involved in the base 
excision repair pathway and repairing DNA when it becomes damaged, this is of interest 
for targeted therapy utilized to treat cancer59. It is suspected that certain tumor cells may 
rely on PARP-mediated DNA repair mechanisms for continued survival and growth. 
These tumors could be sensitive to the inhibition of PARP. When used as a targeted 
therapy, a PARP inhibitor can block PARP and may stop the cancer cells from repairing 
their damaged DNA which then leads to apoptosis of the cancer cells.  
Figure 10: PARP Inhibitor Action72 
 
This figure demonstrates how a PARP inhibitor interferes with the process of DNA repair 





 BRCA1 and BRCA2 are tumor suppressor genes that are commonly found in 
cancers, including familial pancreatic cancer. These genes are involved in the repair of 
DNA. These are the genes that are targeted by PARP inhibitors. This suggests BRCA1 
and BRCA2 as genetic markers for targeted therapy. A deleterious germline mutation of 
BRCA1 and/or BRCA2 can demonstrate loss of expression of these genes and thus loss 
of tumor suppressor function73. Thus this mutation can be used as a valid predictive 
biomarker for targeted therapy by PARP inhibitors71.      
PARP inhibitors are currently FDA approved as oral agents in the treatment of 
ovarian, breast, and pancreatic cancer that harbor or are suspected to harbor germline 
BRCA mutations. Some studies have even demonstrated that PARP is upregulated in 
certain cancers that express BRCA1 mutations. 
Olaparib was first approved in 2014 by the FDA to treat advanced ovarian cancer 
with defective BRCA genes. This can be used as a first-line maintenance treatment for 
patients with advanced ovarian cancer following first-line platinum-based chemotherapy. 
The study that was evaluated for FDA approval was a randomized clinical trial where 
patients were split into groups receiving either olaparib or placebo. While the study is not 
complete yet and thus the data is immature, there was a statistical significance in 
progression-free survival when olaparib was compared to placebo. In another clinical 
trial, patients who had recurrent ovarian cancer and BRCA mutations were studied. They 
were again divided into 2 groups receiving either olaparib or placebo. The results were 
immature but demonstrated significant improvement in progression-free survival. 
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Patients in the group receiving olaparib had a median progression-free survival of 19.1 
months in comparison to the group receiving the placebo who had a median progression-
free survival of 5.5 months74. In another study evaluated by the FDA for olaparib use in 
ovarian cancer, the study group had a BRCA mutation and been treated with two prior 
lines of therapy. The patients who received olaparib had significant results with a median 
progression-free survival of 8.4 months. The median overall survival of the olaparib 
group was 29.8 months. The placebo group had a median progression-free survival of 4.8 
months and a median overall survival of 27.8 months. In a study where patients had 
received three prior lines of therapy, patients in the olaparib group demonstrated a 
significant objective response rate of 34% with a median duration of response of 7.9 
months. These results in advanced ovarian cancer with BRCA mutations do show 
promising response rates of tumors and a significant increase in survival rates using 
targeted therapy PARP inhibitors.  
Olaparib has also been evaluated and approved by the FDA for treatment of 
metastatic breast cancer in patients with germline BRCA mutations who have already had 
a form of chemotherapy treatment. In a randomized clinical trial, patients were divided 
into groups receiving either olaparib or chemotherapy. The patients who received 
olaparib exhibited a significant improvement in progression-free survival with a median 
of 7.0 months compared to the placebo group who had a median progression free survival 
of 4.2 months74. The olaparib group also showed an objective response rate of 52% 
compared to the placebo of 23%. These results demonstrate an increase in disease free 
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survival with olaparib and can possibly correlate to an increase in quality of life for 
patients with metastatic breast cancer.  
The FDA just recently approved olaparib as a treatment option for patients with 
pancreatic cancer in December 201975. This treatment is reserved for patients who 
present with metastatic pancreatic cancer who have a BRCA mutation and whose disease 
has not progressed after at least 16 weeks of first-line chemotherapy treatment. The study 
that was evaluated for efficacy was a global, randomized phase 3 trial of 154 patients 
who were divided into groups receiving either PARP inhibitor targeted therapy or 
placebo tablets. The patients who participated in the trial had mutations in BRCA1, 
mutations in BRCA2, or mutations in both BRCA1 and BRCA2. Patients in the group 
receiving treatment with olaparib had significant survival results as the median 
progression-free survival was 7.4 months compared to the 3.8 months found in the 
placebo group. The Kaplan-Meier curve between the two trial groups support evidence of 
a 47% reduction in risk of disease progression or death with treatment of olaparib 
compared to placebo treatment75. At the 6-month point in the study, there were 
approximately twice as many patients alive and free from disease progression in the 
olaparib group as there were in the placebo group. At the 2 year point in the study, 
disease progression was absent in 22.1% of patients in the olaparib group versus 9.6% of 




Figure 11: Olaparib Survival Curves for PDAC Patients75 
This figure demonstrates progression-free survival and overall survival estimates of the 
clinical trial that compared treatment with olaparib to placebo treatment. Panel A shows 
Kaplan–Meier is an estimate of progression-free survival in the olaparib group and the 
placebo group. Panel B shows Kaplan–Meier estimates of overall survival in the olaparib 
group and the placebo group.      
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 While the effects of overall survival cannot be determined with significance yet, 
pancreatic cancer with BRCA mutations has certainly demonstrated a positive response 
to PARP inhibitor targeted therapy. Of course, this therapy is of best benefit to the PDAC 
cases who present with BRCA mutations. The significant survival results that were 
indicated by previous clinical studies of patients with ovarian and breast cancers using 
olaparib are hopeful for the potential survival benefit of patients with pancreatic cancer. 
Olaparib was evaluated and FDA approved for ovarian and breast cancers a few years 
prior to its approval for pancreatic cancer. The approval for PARP inhibitors in pancreatic 
cancer is very recent as it was just instated in December 2019. With time and some more 
research, it is possible that some modifications can improve the efficacy of this targeted 
therapy and potentially improve survival benefit even further for patients with pancreatic 
cancer. Olaparib is definitely progress in the field of targeted therapy for pancreatic 
cancer and with more research and modifications could one day even contribute to a 




DISCUSSION AND CONCLUSION 
 Receiving a diagnosis of pancreatic cancer can be very difficult news. It can be a 
challenge to choose the best treatment option. There are a number of variables that have 
to be considered when choosing an approach to treatment. These include stage at 
diagnosis, the size and location of the tumor, and whether or not metastasis has occurred. 
Genetic profiling can also be done to assess whether or not the patient would benefit from 
any targeted therapy options. 
If the patient is diagnosed at an earlier stage and the tumor is considered to be 
resectable than surgical resection should be highly considered and should most likely be 
done. Surgical resection is still considered the only option that has the potential to cure 
pancreatic cancer. Based on where the tumor is located, at the head or tail or body of the 
pancreas, the patient may have a choice between the Whipple procedure or a distal 
pancreatectomy. Chemotherapy can also be considered along with surgery. The patient 
may opt to do neoadjuvant chemotherapy to try and shrink the tumor and increase the 
success of the surgery. This may be considered a little bit riskier but can be done for a 
short period of time if it is suspected that the tumor isn’t progressing rapidly. After the 
surgery, the patient should also choose an adjuvant chemotherapy to prevent the 
recurrence of tumor.  
If a patient is diagnosed at a stage of pancreatic cancer that is borderline 
resectable there may be a different approach to treatment. Neoadjuvant therapy may be 
considered before the surgery if there is a chance that shrinking the tumor could make it 
more likely to be resectable and increase the chances of completely excising the tumor 
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during surgery. If the cancer is suspected to be rapidly progressing, then there may not be 
enough time to do neoadjuvant therapy and surgical resection should be done as soon as 
possible. The patient’s overall health should be evaluated before the surgery is performed 
on a borderline resectable tumor to see if the individual is a suitable candidate for major 
surgery. Adjuvant chemotherapy should also be considered after surgery to decrease the 
likelihood of cancer recurrence. If surgery is not performed, then the patient must 
consider what treatment options would be most preferred for them. There options may 
include chemotherapy, targeted therapy, or a combination of both. Genetic profiling 
would have to be done to evaluate if a patient would benefit from targeted therapy and if 
so which targeted therapy to choose, erlotinib or olaparib.  
A patient may also be diagnosed at an advanced stage where surgical resection is 
not recommended. At this point the surgery may be too much of a risk, there may have 
been too much metastasis, or the patient may not be a suitable candidate because of poor 
health. The patient may consider therapies for management to increase survival: overall 
survival and/or progression-free survival. Another option the patient may consider is 
palliative care. To increase management efficacy, genetic profiling may be done to see if 
the patient would benefit from a targeted therapy option.  
While there has been progress made in the treatment of pancreatic cancer, it still 
remains a very challenging disease with poor prognosis and limited options. Personalized 
medicine has ignited some hope though as it has provided some targeted therapy options 
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